New York, NY, United States of America

Tom Neubert

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: New York University, Regents of the University of Minnesota. Active years: 2021.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Tom Neubert

Introduction

Tom Neubert is an accomplished inventor based in New York, NY (US). He has made significant contributions to the field of biotechnology, particularly in the area of regulatory T-cells. His work has implications for various therapeutic applications, showcasing his innovative spirit and dedication to advancing scientific knowledge.

Latest Patents

Neubert holds a patent titled "Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)." This patent outlines methods and compositions aimed at enhancing the suppressive function of Tregs, which play a crucial role in maintaining immune system balance. His innovative approach in this area has the potential to impact treatments for autoimmune diseases and other conditions.

Career Highlights

Throughout his career, Neubert has been associated with prestigious institutions such as New York University and the Regents of the University of Minnesota. His work at these institutions has allowed him to collaborate with leading researchers and contribute to groundbreaking studies in immunology.

Collaborations

Neubert has worked alongside notable colleagues, including Cameron McDonald-Hyman and James Muller. These collaborations have enriched his research and expanded the impact of his innovations in the scientific community.

Conclusion

Tom Neubert's contributions to the field of biotechnology, particularly through his patent on regulatory T-cells, highlight his role as a significant inventor. His work continues to inspire advancements in medical research and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…